J

Johnson & Johnson

Makes prescription drugs and medical devices

Global Financial Reporting Senior Analyst

Full-TimeUpdated on 10/15/2026Deadline 10/23/26
No salary listed
Mid
Bachelor's, MBA
Taguig, Metro Manila, Philippines
HybridHybrid setup; onsite reporting is required as needed.
AccountingFinancial Accounting

About the job

Requirements
  • A bachelor's degree or equivalent is required, preferably in Accounting, Finance, Business, or a related field.
  • At least 3 years of professional experience in financial reporting, accounting, account-to-report, general ledger, reconciliation, intercompany, accounts payable, accounts receivable, or related finance operations.
  • Strong understanding of accounting principles, financial reporting processes, reconciliations, journal entries, and close activities.
  • Ability to analyze financial data, investigate variances, resolve issues, and prepare reports compliant with standards and controls.
  • Strong attention to detail, documentation discipline, and commitment to compliance and audit readiness.
  • Ability to manage multiple priorities, work efficiently under tight deadlines, and remain effective during close periods.
  • Willingness to work night shifts or shifting schedules as required to support global assignments across the Americas, EMEA, and Asia.
  • Willingness to work in a hybrid setup and report onsite as required.
Responsibilities
  • Perform daily, monthly, and quarterly financial reporting and accounting activities across assigned processes, platforms, and legal entities.
  • Support CFIN ATR processes, including data replication monitoring, error analysis, manual journal entry preparation or posting, reconciliation package preparation, and close-related reporting activities.
  • Prepare, analyze, and support reconciliations for source ERP to CFIN data, including sales, trial balance, quantity, journal entry, and other interface or reporting reconciliations as required.
  • Support financial reporting submissions and related activities, including data validation, issue resolution, report preparation, and coordination with responsible teams before close deadlines.
  • Ensure the completeness, accuracy, and validity of actuals reported within assigned process, platform, and entity scope.
  • Investigate and resolve accounting, reporting, or data quality issues where procedures may not be fully defined, escalating risks and dependencies as needed.
  • Maintain proper documentation, audit trails, and evidence to support financial reporting, reconciliation, journal entry, and control requirements.
  • Handle confidential financial information with appropriate care and in line with company policies.
  • Comply with applicable laws and regulations and follow guidelines in the J&J Credo.
  • Execute assigned activities in accordance with global policies, worldwide procedures, internal controls, audit requirements, SOX controls, and service level commitments.
  • Support review, approval, and evidence preparation for financial reporting controls, including reconciliation controls, journal entry controls, access or system-related controls, and close sign-offs where applicable.
  • Identify control gaps, data quality risks, process issues, or reporting defects and recommend practical actions to remediate or prevent recurrence.
  • Partner with regional and global stakeholders to coordinate issue resolution, align close status, clarify reporting requirements, and support timely decision-making.
  • Work with SMEs, analysts, operational teams, LTM/technology partners, Data Quality, Finance Data Management, Compliance, and GPO teams on process and operational matters.
  • Support cross-sector, cross-region, and cross-process alignment by maintaining consistent documentation, standard practices, and a global approach to reporting and reconciliation activities.
  • Communicate timely updates to stakeholders, explain variances or defects, and escalate issues with clear facts and proposed next steps.
  • Identify and pursue opportunities to improve efficiency, standardization, automation, data quality, and reporting reliability.
  • Support process improvements, transformation initiatives, system enhancements, testing, and stabilization activities related to CFIN, financial reporting, and close processes.
  • Contribute practical solutions that reduce manual effort, strengthen controls, improve auditability, and support global process standardization.
  • Lead or participate in regional, global, or cross-functional duties as assigned.
Desired Qualifications
  • CPA, CMA, MBA, or another relevant finance certification.
  • Experience in a Global Account-to-Report function, shared service center, multinational corporation, or BPO environment.
  • Experience with SAP, SAP Central Finance, BlackLine, BRAVO, TM1, Analysis for Office, or other ERP and reporting tools.
  • Solid US GAAP knowledge and understanding of SOX or internal control requirements.
  • Advanced Microsoft Excel skills and proficiency in Microsoft applications.
  • Digital, automation, reporting, or process improvement experience.
  • Ability to handle ambiguity and fluid situations with a pragmatic, solution-oriented approach.

About the company

Johnson & Johnson develops prescription medicines and makes medical devices for hospitals, and unlike most big drugmakers, it runs both businesses under one roof. In 2015, its Darzalex became the first antibody drug approved for multiple myeloma, a blood cancer. Its medicines treat cancer, immune diseases such as psoriasis, and mental illnesses such as depression, and patented drugs bring in most of its sales. Its MedTech unit makes heart pumps, catheters that treat irregular heartbeats, surgical sutures, and Acuvue contact lenses. It was founded in 1886 to make sterile surgical dressings, is based in New Brunswick, New Jersey, and spun off its consumer brands, such as Tylenol and Band-Aid, as Kenvue in 2023.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, New Jersey

Founded

1886

Get referred to Johnson & Johnson

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Cancer drugs drive growth: oncology sales rose 17% to $7.4 billion in the June 2026 quarter, 29% of the total.
  • Stock grants have gained value: J&J shares rose 58% in the year to September 2026, versus 23% for Pfizer.
  • Students have a way in: J&J listed 1,897 open jobs in October 2026, including 201 internships, co-ops and early-career roles.

What critics are saying

  • Its key immune drug trails: AbbVie's Skyrizi outsold Tremfya $5.5 billion to $2.0 billion in the June 2026 quarter.
  • Orthopedics is leaving J&J: in September 2026, it was negotiating a $20 billion sale to buyout firm Apollo.
  • Baby powder suits remain costly: in July 2026, J&J agreed to pay $5.5 billion to end about 76,000 cancer claims.

What makes Johnson & Johnson unique

  • Its debt is rated safer than America's: S&P's top AAA rating goes to only two US companies, J&J and Microsoft.
  • Employees rank above shareholders: J&J's 1943 Credo lists duties to patients, then staff and communities, with stockholders last.
  • Its psoriasis pill is a first: Icotyde, approved March 2026, blocks an immune signal rivals target only by injection.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays
  • Remote Work Options
  • Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

-2%

1 year growth

-2%

2 year growth

-2%
Yahoo Finance
Oct 20th, 2026
Johnson & Johnson and Amgen beat the market in 2026, but can the dividend stocks keep going?

Johnson & Johnson and Amgen, two dividend stocks that have beaten the broader market this year, could suit investors bracing for a possible crash. J&J's latest quarter beat expectations, and it slightly raised its 2026 guidance. But its medtech unit is struggling, as demand for the Impella heart pump has fallen amid safety questions and a US Class 1 recall. Long-term, it has new drugs, a robotic surgery system approved in the US, and a proposed $5.5 billion talc settlement. It is a Dividend King with 64 straight years of payout increases. Amgen's second-quarter revenue rose 10% to $10.1 billion, despite pressure on Tavneos and falling denosumab sales. It has raised payouts 152% over a decade and offers a 2.3% forward yield, against 1.1% for the S&P 500.

Yahoo Finance
Oct 17th, 2026
Johnson & Johnson dips after $25.4B quarter: buy the Dividend King?

Johnson & Johnson shares fell after the healthcare group reported third-quarter results, despite a beat-and-raise quarter. Revenue rose 5.9% to $25.4 billion, while adjusted earnings per share fell 7.5% to $2.59, a drop attributed mostly to acquisitions. Innovative medicine sales rose 7.7% to $16.8 billion, led by cancer drug Darzalex ($4.2 billion) and Tremfya ($2.4 billion, up 68.3%). The company raised its 2026 operational sales guidance to $100.7 billion at the midpoint, from $100.6 billion. Medtech revenue grew just 2.5% to $8.6 billion, which drove the share dip. Safety and efficacy concerns over its Impella heart pumps hurt the cardiovascular unit abroad. The company has raised its dividend for 64 consecutive years, making it a Dividend King.

Yahoo Finance
Oct 14th, 2026
J&J shares fall 6% as MedTech sales miss forecasts despite $25.4B revenue beat

Johnson & Johnson shares fell 6% after its medical device sales missed forecasts, even though third-quarter results beat estimates. Revenue was $25.4 billion, above the $25.37 billion expected. Adjusted earnings were $2.59 per share, $0.07 above estimates. MedTech sales rose 2.5% to $8.6 billion, below the $8.71 billion forecast, and marked a second straight quarterly miss. The company blamed the Middle East conflict, European austerity, and pricing pressure in China. Pharmaceutical sales rose 7.7% to $16.76 billion. Net earnings fell to $210 million from $2.12 a year earlier, hit by about $7 billion in talc settlement and deal costs. The company raised its full-year sales outlook to about $101.2 billion and said it is leaning toward spinning off its orthopedics unit, DePuy Synthes, by mid-2027.

Yahoo Finance
Oct 13th, 2026
J&J medtech sales rise just 2.5% to $8.64B as Abiomed slump weighs on cardiovascular

Johnson & Johnson's medtech sales rose 2.5% year over year to $8.64 billion in the third quarter, missing internal expectations. Growth has slowed for two quarters in a row, after rising more than 7% in the first quarter and last year's fourth quarter. The cardiovascular unit grew 4.3% to $2.31 billion. Its Abiomed business, bought in 2022 for $16.6 billion, fell 2.3% to $412 million. Tim Schmid, worldwide chairman of medtech, blamed lower patient volume after an unfavourable UK study of the Impella heart device. He called the setback temporary and said pressure also came from sales outside the US. J&J expects results from its PROTECT IV study of nearly 1,300 patients next year.

Yahoo Finance
Oct 13th, 2026
Memory stocks slide on Chinese chip breakthrough as UnitedHealth and Goldman beat estimates

US stock futures were mixed on Tuesday as investors weighed a wave of earnings reports. Dow futures rose 0.9%, S&P 500 futures slipped 0.1%, and Nasdaq futures fell 0.7%. Memory stocks fell for a second day after a Chinese chipmaker, CXMT, said it had made a breakthrough in memory chip production. Roundhill Memory ETF fell more than 5% in premarket trading. UnitedHealth rose more than 2% after it earned an adjusted $4.69 per share on $112.69 billion in revenue, beating estimates. It raised its full-year earnings outlook to at least $20.50 per share. Goldman Sachs gained more than 3% on strong results. JPMorgan Chase, Wells Fargo, and Citigroup fell short in parts of their reports. Johnson & Johnson fell 2% after $25.40 billion in sales narrowly missed estimates, though it raised its full-year forecasts.